![Margaret Liu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Margaret Liu
Director/Board Member at
NANOBIOTIX
Net worth: 201 114 $ as of 2026-06-29
Profile
Margaret A. Liu is currently Chief Executive Officer at Pax Therapeutics, Inc. since 2020.
Chairperson at International Society For Vaccines since 2017.
Independent Director at Ipsen SA since 2017.
Independent Director at MacroGenics, Inc. since 2023.
Director at Transgene, Inc. Member at American Society for Clinical Investigation.
Member-Supervisory Board at Nanobiotix SA. Formerly Vice Chairman at Transgene SA from 2000 to 2006.
Director at Sangamo Therapeutics, Inc. from 2005 to 2009.
Director and Senior Director-Virus & Cell Biology at Merck Research Laboratories Massachusetts LLC from 1990 to 1997.
Director at Keystone Symposia.
Director and President Emerita at International Vaccine Institute.
Director at Adjuvance Technologies, Inc. Vice President-Vaccines & Gene Therapy at Chiron Corp.
from 1997 to 2000.
Professor at Karolinska Institutet from 2003 to 2007.
Principal at ProTherImmune.
Education includes undergraduate studies at The Colorado College and a doctorate from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IPSEN SA 0% | 2025-12-30 | 689 ( 0% ) | 132 969 $ | 2026-06-29 |
MACROGENICS, INC. 0.02% | 2026-05-18 | 14,750 ( 0.02% ) | 68 145 $ | 2026-06-29 |
Margaret Liu active positions
| Companies | Position | Start |
|---|---|---|
| IPSEN | Director/Board Member | 2017-06-06 |
| MACROGENICS, INC. | Director/Board Member | 2023-01-02 |
| NANOBIOTIX | Director/Board Member | - |
Transgene, Inc.
 Transgene, Inc. Founded in 1982, Transgene, Inc. is a clinical-stage biotechnology company specializing in cancer immunotherapy through viral vector engineering. The company is based in Dover, DE. The company develops individualized therapeutic vaccines using its proprietary myvac® platform, which designs personalized vaccines targeting tumor-specific neoantigens to stimulate the patient’s immune system against early-stage solid tumors. Its lead product, TG4050, is an individualized neoantigen vaccine in randomized phase 1/2 trials as an adjuvant treatment for HPV-negative head and neck squamous cell carcinoma. Transgene’s pipeline also includes oncolytic virus candidates BT-001 and TG6050, engineered to express immune-modulating antibodies and cytokines, evaluated in early-phase clinical trials for various solid tumors. | Director/Board Member | - |
Pax Therapeutics, Inc. | Chief Executive Officer | 2019-12-31 |
International Society For Vaccines | Chairman | 2016-12-31 |
American Society for Clinical Investigation
 American Society for Clinical Investigation BiotechnologyHealth Technology Provides clinical investigation services | Corporate Officer/Principal | - |
Former positions of Margaret Liu
| Companies | Position | End |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Director/Board Member | 2009-06-03 |
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 2006-12-31 |
| ░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Margaret Liu
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
74
1st degree connections
18
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 18 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Transgene SA
 Transgene SA BiotechnologyHealth Technology Designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer | Health Technology |
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
MacroGenics, Inc.
 MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado College
 The Colorado College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Society for Clinical Investigation
American Society for Clinical Investigation BiotechnologyHealth Technology Provides clinical investigation services | Health Technology |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Keystone Symposia
 Keystone Symposia Miscellaneous Commercial ServicesCommercial Services Operates nonprofit organization that convenes open, peer-reviewed conferences across a broad range of the life sciences | Commercial Services |
Nanobiotix SA
 Nanobiotix SA Pharmaceuticals: MajorHealth Technology Develops and manufactures nanotherapeutics for treatment of cancer | Health Technology |
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services Develops and distributes vaccines | Commercial Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Transgene, Inc.
Transgene, Inc. Founded in 1982, Transgene, Inc. is a clinical-stage biotechnology company specializing in cancer immunotherapy through viral vector engineering. The company is based in Dover, DE. The company develops individualized therapeutic vaccines using its proprietary myvac® platform, which designs personalized vaccines targeting tumor-specific neoantigens to stimulate the patient’s immune system against early-stage solid tumors. Its lead product, TG4050, is an individualized neoantigen vaccine in randomized phase 1/2 trials as an adjuvant treatment for HPV-negative head and neck squamous cell carcinoma. Transgene’s pipeline also includes oncolytic virus candidates BT-001 and TG6050, engineered to express immune-modulating antibodies and cytokines, evaluated in early-phase clinical trials for various solid tumors. | |
Adjuvance Technologies, Inc.
 Adjuvance Technologies, Inc. Pharmaceuticals: GenericHealth Technology Adjuvance Technologies, Inc.is a biopharmaceutical company. The company was founded by Jeffrey Gardner and is headquartered in Lincoln, NE. | Health Technology |
ProTherImmune | |
International Society For Vaccines | |
Pax Therapeutics, Inc. |
- Stock Market
- Insiders
- Margaret Liu
Choose MarketScreener 
